EcoR1 discloses 6.8% Voyager Therapeutics (VYGR) ownership stake
Rhea-AI Filing Summary
EcoR1 Capital and affiliates reported a sizable ownership position in Voyager Therapeutics, Inc. common stock. EcoR1 Capital, LLC and its control person Oleg Nodelman each beneficially own 4,002,847 shares, representing 6.8% of Voyager’s common stock. EcoR1 Capital Fund Qualified, L.P. directly holds 3,756,988 shares, or 6.4% of the class.
The filing shows no sole voting or dispositive power; all authority is shared among the reporting persons. They state the shares were acquired and are held in the ordinary course of business and not for the purpose, or with the effect, of changing or influencing control of Voyager Therapeutics.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in Voyager Therapeutics (VYGR) did EcoR1 report?
EcoR1 Capital, LLC and Oleg Nodelman each reported beneficial ownership of 4,002,847 Voyager Therapeutics common shares, representing 6.8% of the class. This stake reflects both existing outstanding shares and shares issued upon exercise of prefunded warrants.
How did the reporting persons calculate their percentage ownership in Voyager Therapeutics (VYGR)?
The reported percentages are based on 58,932,628 Voyager Therapeutics common shares outstanding. This figure includes 55,600,084 shares outstanding on November 3, 2025, plus 3,332,544 shares issued to the reporting persons upon exercise of prefunded warrants.
What roles do EcoR1 and Oleg Nodelman play in relation to the Voyager Therapeutics (VYGR) stake?
EcoR1 Capital, LLC acts as general partner and investment adviser to funds including the Qualified Fund. Oleg Nodelman is the control person of EcoR1, and both he and EcoR1 disclaim beneficial ownership beyond their pecuniary interests.